These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20477603)

  • 1. Interleukin-18 treatment options for inflammatory diseases.
    Dinarello CA; Kaplanski G
    Expert Rev Clin Immunol; 2005 Nov; 1(4):619-32. PubMed ID: 20477603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-18 and the pathogenesis of inflammatory diseases.
    Dinarello CA
    Semin Nephrol; 2007 Jan; 27(1):98-114. PubMed ID: 17336692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease.
    Kawashima M; Yamamura M; Taniai M; Yamauchi H; Tanimoto T; Kurimoto M; Miyawaki S; Amano T; Takeuchi T; Makino H
    Arthritis Rheum; 2001 Mar; 44(3):550-60. PubMed ID: 11263769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-18 and the treatment of rheumatoid arthritis.
    Dinarello CA
    Rheum Dis Clin North Am; 2004 May; 30(2):417-34, ix. PubMed ID: 15172050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
    Dejica D
    Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation.
    Dinarello CA
    Curr Opin Pharmacol; 2004 Aug; 4(4):378-85. PubMed ID: 15251132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interleukin 10 in disseminated lupus erythematosus].
    Emilie D
    J Soc Biol; 2002; 196(1):19-21. PubMed ID: 12134628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients: common transcriptional regulatory mechanism between interleukin-8 and interleukin-1beta.
    Onodera S; Nishihira J; Koyama Y; Majima T; Aoki Y; Ichiyama H; Ishibashi T; Minami A
    Arthritis Rheum; 2004 May; 50(5):1437-47. PubMed ID: 15146413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated titers of cell-free interleukin 2 receptor in serum of lupus mice.
    Balderas RS; Josimovic-Alasevic O; Diamantstein T; Dixon FJ; Theofilopoulos AN
    J Immunol; 1987 Sep; 139(5):1496-500. PubMed ID: 3114368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical implication of IL-10 in patients with immune and inflammatory diseases].
    Ishida H
    Rinsho Byori; 1994 Aug; 42(8):843-52. PubMed ID: 7933621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis.
    Dinarello CA
    Kidney Int Suppl; 1992 Oct; 38():S68-77. PubMed ID: 1328757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
    Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
    J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1beta polymorphisms in Colombian patients with autoimmune rheumatic diseases.
    Camargo JF; Correa PA; Castiblanco J; Anaya JM
    Genes Immun; 2004 Dec; 5(8):609-14. PubMed ID: 15470475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-1 and interleukin-1 receptor antagonist.
    Dinarello CA
    Nutrition; 1995; 11(5 Suppl):492-4. PubMed ID: 8748206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine signal regulation and autoimmune disorders.
    Nishimoto N
    Autoimmunity; 2005 Aug; 38(5):359-67. PubMed ID: 16227151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The weight of interleukin-6 in B cell-related autoimmune disorders.
    Youinou P; Jamin C
    J Autoimmun; 2009; 32(3-4):206-10. PubMed ID: 19307104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
    Pallua N; Low JF; von Heimburg D
    Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-18.
    Dinarello CA
    Methods; 1999 Sep; 19(1):121-32. PubMed ID: 10525448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 6: from bench to bedside.
    Nishimoto N; Kishimoto T
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):619-26. PubMed ID: 17075601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.